I am a Board Director at Novocure and a physician-scientist focused on oncology innovation, clinical development strategy, and translational medicine. As Professor of Clinical Medicine at Weill Cornell Medicine, I bring over two decades of leadership in precision oncology and clinical research. I help life sciences organizations translate scientific breakthroughs into clinically meaningful therapies by integrating frontline clinical insight with development strategy, regulatory pathways, and real-world adoption.
I direct the Pancreatic Cancer Clinical Research Program and the Hereditary Gastrointestinal Cancer Program, advancing novel therapies as a gastrointestinal medical oncologist and translational researcher. As a Principal Investigator for early trials of sacituzumab govitecan (Trodelvy), I contributed to its development and FDA approval. My work spans genomic profiling, biomarker-driven therapies, and collaborations with leading research institutions.
